Xilio Therapeutics (XLO) Research & Development (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Research & Development data on file, last reported at $19.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 139.92% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $67.6 million (up 73.0% YoY), and the FY2025 full-year result was $56.0 million, up 35.98% from the prior year.
• Research & Development grew to $19.8 million in Q1 2026, from $18.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $19.8 million in Q1 2026 to a low of $8.3 million in Q1 2025.
• A 5-year average of $13.4 million and a median of $13.2 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 35.53% in 2024 and soared 139.92% in 2026, its largest moves.
• Tracing XLO's Research & Development over 5 years: stood at $15.0 million in 2022, then slipped by 21.74% to $11.7 million in 2023, then declined by 24.71% to $8.8 million in 2024, then soared by 105.09% to $18.1 million in 2025, then rose by 9.44% to $19.8 million in 2026.
• Business Quant data shows XLO's Research & Development at $19.8 million in Q1 2026, $18.1 million in Q4 2025, and $14.3 million in Q3 2025.